-
1
-
-
84875804295
-
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in
-
Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in. Eur. J. Cancer 2012, 49(2013):1374-1403. 10.1016/j.ejca.2012.12.027.
-
(2012)
Eur. J. Cancer
, vol.49
, Issue.2013
, pp. 1374-1403
-
-
Ferlay, J.1
Steliarova-Foucher, E.2
Lortet-Tieulent, J.3
Rosso, S.4
Coebergh, J.W.W.5
Comber, H.6
-
3
-
-
0036675220
-
Metastasis to bone: causes, consequences and therapeutic opportunities
-
Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2:584-593. 10.1038/nrc867.
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 584-593
-
-
Mundy, G.R.1
-
4
-
-
84947486728
-
The Wnt inhibitor dickkopf-1: a link between breast cancer and bone metastases
-
Mariz K., Ingolf J.-B., Daniel H., Teresa N.J., Erich-Franz S. The Wnt inhibitor dickkopf-1: a link between breast cancer and bone metastases. Clin. Exp. Metastasis 2015, 32:857-866. 10.1007/s10585-015-9750-1.
-
(2015)
Clin. Exp. Metastasis
, vol.32
, pp. 857-866
-
-
Mariz, K.1
Ingolf, J.-B.2
Daniel, H.3
Teresa, N.J.4
Erich-Franz, S.5
-
5
-
-
84901626754
-
Endocrine aspects of bone metastases
-
Hofbauer L.C., Rachner T.D., Coleman R.E., Jakob F. Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol 2014, 2:500-512. 10.1016/S2213-8587(13)70203-1.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 500-512
-
-
Hofbauer, L.C.1
Rachner, T.D.2
Coleman, R.E.3
Jakob, F.4
-
7
-
-
36649001116
-
Bisphosphonates: reducing the risk of skeletal complications from bone metastasis
-
Costa L. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast 2007, 16(Suppl. 3):S16-S20. 10.1016/j.breast.2007.10.005.
-
(2007)
Breast
, vol.16
, pp. S16-S20
-
-
Costa, L.1
-
8
-
-
84863317657
-
Novel aspects of mevalonate pathway inhibitors as antitumor agents
-
Thurnher M., Nussbaumer O., Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin. Cancer Res 2012, 18:3524-3531. 10.1158/1078-0432.CCR-12-0489.
-
(2012)
Clin. Cancer Res
, vol.18
, pp. 3524-3531
-
-
Thurnher, M.1
Nussbaumer, O.2
Gruenbacher, G.3
-
10
-
-
0141756144
-
Role of Rho-family proteins in cell adhesion and cancer
-
Malliri A., Collard J.G. Role of Rho-family proteins in cell adhesion and cancer. Curr. Opin. Cell Biol 2003, 15:583-589. 10.1016/S0955-0674(03)00098-X.
-
(2003)
Curr. Opin. Cell Biol
, vol.15
, pp. 583-589
-
-
Malliri, A.1
Collard, J.G.2
-
11
-
-
1642304545
-
Altered Rho GTPase signaling pathways in breast cancer cells
-
Burbelo P., Wellstein A., Pestell R.G. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res. Treat 2004, 84:43-48. 10.1023/B:BREA.0000018422.02237.f9.
-
(2004)
Breast Cancer Res. Treat
, vol.84
, pp. 43-48
-
-
Burbelo, P.1
Wellstein, A.2
Pestell, R.G.3
-
13
-
-
84870520448
-
Targeting tumor cell metabolism with statins
-
Clendening J.W., Penn L.Z. Targeting tumor cell metabolism with statins. Oncogene 2012, 31:4967-4978. 10.1038/onc.2012.6.
-
(2012)
Oncogene
, vol.31
, pp. 4967-4978
-
-
Clendening, J.W.1
Penn, L.Z.2
-
14
-
-
0036239832
-
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis
-
Wong W.W.L., Dimitroulakos J., Minden M.D., Penn L.Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund, U.K. 2002, 16:508-519. 10.1038/sj.leu.2402476.
-
(2002)
Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund, U.K.
, vol.16
, pp. 508-519
-
-
Wong, W.W.L.1
Dimitroulakos, J.2
Minden, M.D.3
Penn, L.Z.4
-
15
-
-
0026607503
-
Cholesterol inhibition, cancer, and chemotherapy
-
Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet (London, England). 1992, 339:1154-1156.
-
(1992)
Lancet (London, England).
, vol.339
, pp. 1154-1156
-
-
Buchwald, H.1
-
16
-
-
84862908644
-
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
-
Freed-Pastor W.A., Mizuno H., Zhao X., Langerød A., Moon S.-H., Rodriguez-Barrueco R., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258. 10.1016/j.cell.2011.12.017.
-
(2012)
Cell
, vol.148
, pp. 244-258
-
-
Freed-Pastor, W.A.1
Mizuno, H.2
Zhao, X.3
Langerød, A.4
Moon, S.-H.5
Rodriguez-Barrueco, R.6
-
18
-
-
28844490054
-
Statins and cancer prevention
-
Demierre M.-F., Demierre M.-F., Higgins P.D.R., Higgins P.D.R., Gruber S.B., Gruber S.B., et al. Statins and cancer prevention. Nat. Rev. Cancer 2005, 5:930-942. 10.1038/nrc1751.
-
(2005)
Nat. Rev. Cancer
, vol.5
, pp. 930-942
-
-
Demierre, M.-F.1
Demierre, M.-F.2
Higgins, P.D.R.3
Higgins, P.D.R.4
Gruber, S.B.5
Gruber, S.B.6
-
19
-
-
33645047418
-
The role of statins in cancer therapy
-
Hindler K., Cleeland C.S., Rivera E., Collard C.D. The role of statins in cancer therapy. Oncologist 2006, 11:306-315. 10.1634/theoncologist.11-3-306.
-
(2006)
Oncologist
, vol.11
, pp. 306-315
-
-
Hindler, K.1
Cleeland, C.S.2
Rivera, E.3
Collard, C.D.4
-
20
-
-
84887410335
-
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates
-
Gronich N., Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat. Rev. Clin. Oncol 2013, 10:625-642. 10.1038/nrclinonc.2013.169.
-
(2013)
Nat. Rev. Clin. Oncol
, vol.10
, pp. 625-642
-
-
Gronich, N.1
Rennert, G.2
-
21
-
-
84904960449
-
Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities
-
Clézardin P. Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. Bonekey Rep 2013, 2:267. 10.1038/bonekey.2013.1.
-
(2013)
Bonekey Rep
, vol.2
, pp. 267
-
-
Clézardin, P.1
-
22
-
-
78650304661
-
Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class
-
Clézardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011, 48:71-79. 10.1016/j.bone.2010.07.016.
-
(2011)
Bone
, vol.48
, pp. 71-79
-
-
Clézardin, P.1
-
23
-
-
0032491037
-
Reduction in new metastases in breast cancer with adjuvant clodronate treatment
-
Diel I.J., Solomayer E.F., Costa S.D., Gollan C., Goerner R., Wallwiener D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med 1998, 339:357-363. 10.1056/NEJM199808063390601.
-
(1998)
N. Engl. J. Med
, vol.339
, pp. 357-363
-
-
Diel, I.J.1
Solomayer, E.F.2
Costa, S.D.3
Gollan, C.4
Goerner, R.5
Wallwiener, D.6
-
24
-
-
51349163043
-
Bisphosphonates: mechanism of action and role in clinical practice
-
Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc 2008, 83:1032-1045. 10.4065/83.9.1032.
-
(2008)
Mayo Clin. Proc
, vol.83
, pp. 1032-1045
-
-
Drake, M.T.1
Clarke, B.L.2
Khosla, S.3
-
25
-
-
84856848340
-
Zoledronic acid in breast cancer: latest findings and interpretations
-
Gnant M. Zoledronic acid in breast cancer: latest findings and interpretations. Ther. Adv. Med. Oncol 2011, 3:293-301. 10.1177/1758834011420599.
-
(2011)
Ther. Adv. Med. Oncol
, vol.3
, pp. 293-301
-
-
Gnant, M.1
-
26
-
-
84977916386
-
Breast-cancer adjuvant therapy with zoledronic acid
-
Coleman R.E., Marshall H., Cameron D., Dodwell D., Burkinshaw R., Keane M., et al. Breast-cancer adjuvant therapy with zoledronic acid. Breast-Cancer Adjuv. Ther. with Zoledronic Acid 2011, 365:1-10. 10.1056/NEJMoa1105195.
-
(2011)
Breast-Cancer Adjuv. Ther. with Zoledronic Acid
, vol.365
, pp. 1-10
-
-
Coleman, R.E.1
Marshall, H.2
Cameron, D.3
Dodwell, D.4
Burkinshaw, R.5
Keane, M.6
-
27
-
-
84882297750
-
Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: retrospective analysis results in an unselected single-center cohort
-
Hadji P., Frank M., Jakob A., Siebers J.W. Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: retrospective analysis results in an unselected single-center cohort. J. Bone Oncol 2013, 2:2-10. 10.1016/j.jbo.2013.01.001.
-
(2013)
J. Bone Oncol
, vol.2
, pp. 2-10
-
-
Hadji, P.1
Frank, M.2
Jakob, A.3
Siebers, J.W.4
-
28
-
-
84864031857
-
Statins and cancer: current and future prospects
-
Osmak M. Statins and cancer: current and future prospects. Cancer Lett 2012, 324:1-12. 10.1016/j.canlet.2012.04.011.
-
(2012)
Cancer Lett
, vol.324
, pp. 1-12
-
-
Osmak, M.1
-
29
-
-
67650767002
-
Adverse effects of bisphosphonates: implications for osteoporosis management
-
quiz 638
-
Kennel K.A., Drake M.T. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin. Proc 2009, 84:632-637. quiz 638. 10.4065/84.7.632.
-
(2009)
Mayo Clin. Proc
, vol.84
, pp. 632-637
-
-
Kennel, K.A.1
Drake, M.T.2
-
30
-
-
84948380673
-
Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins
-
Göbel A., Browne A.J., Thiele S., Rauner M., Hofbauer L.C., Rachner T.D. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. Breast Cancer Res. Treat 2015, 623-631. 10.1007/s10549-015-3624-8.
-
(2015)
Breast Cancer Res. Treat
, pp. 623-631
-
-
Göbel, A.1
Browne, A.J.2
Thiele, S.3
Rauner, M.4
Hofbauer, L.C.5
Rachner, T.D.6
-
31
-
-
81255185444
-
Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors
-
Berndt N., Sebti S.M. Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nat. Protoc 2011, 6:1775-1791. 10.1038/nprot.2011.387.
-
(2011)
Nat. Protoc
, vol.6
, pp. 1775-1791
-
-
Berndt, N.1
Sebti, S.M.2
-
32
-
-
84901653151
-
Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
-
Benad-Mehner P., Thiele S., Rachner T.D., Göbel A., Rauner M., Hofbauer L.C. Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. J. Bone Oncol 2014, 3:18-24. 10.1016/j.jbo.2013.11.001.
-
(2014)
J. Bone Oncol
, vol.3
, pp. 18-24
-
-
Benad-Mehner, P.1
Thiele, S.2
Rachner, T.D.3
Göbel, A.4
Rauner, M.5
Hofbauer, L.C.6
-
33
-
-
84901672375
-
Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
-
Wilke M., Göbel A., Rauner M., Benad-Mehner P., Schütze N., Füssel S., et al. Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells. J. Bone Oncol 2014, 3:10-17. 10.1016/j.jbo.2014.02.001.
-
(2014)
J. Bone Oncol
, vol.3
, pp. 10-17
-
-
Wilke, M.1
Göbel, A.2
Rauner, M.3
Benad-Mehner, P.4
Schütze, N.5
Füssel, S.6
-
34
-
-
0034912833
-
A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro
-
Yoneda T., Williams P.J., Hiraga T., Niewolna M., Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Miner. Res 2001, 16:1486-1495. 10.1359/jbmr.2001.16.8.1486.
-
(2001)
J. Bone Miner. Res
, vol.16
, pp. 1486-1495
-
-
Yoneda, T.1
Williams, P.J.2
Hiraga, T.3
Niewolna, M.4
Nishimura, R.5
-
35
-
-
0036792257
-
Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo
-
Bendre M.S., Gaddy-Kurten D., Mon-Foote T., Akel N.S., Skinner R.A., Nicholas R.W., et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002, 62:5571-5579.
-
(2002)
Cancer Res
, vol.62
, pp. 5571-5579
-
-
Bendre, M.S.1
Gaddy-Kurten, D.2
Mon-Foote, T.3
Akel, N.S.4
Skinner, R.A.5
Nicholas, R.W.6
-
36
-
-
1042304249
-
Models of breast cancer: is merging human and animal models the future?
-
Kim J.B., O'Hare M.J., Stein R. Models of breast cancer: is merging human and animal models the future?. Breast Cancer Res 2004, 6:22-30. 10.1186/bcr645.
-
(2004)
Breast Cancer Res
, vol.6
, pp. 22-30
-
-
Kim, J.B.1
O'Hare, M.J.2
Stein, R.3
-
37
-
-
80053426842
-
Review series Targeted therapies for breast cancer
-
Higgins M.J., Baselga J. Review series Targeted therapies for breast cancer. J. Clin. Invest 2011, 121:3797-3803. 10.1172/JCI57152.with.
-
(2011)
J. Clin. Invest
, vol.121
, pp. 3797-3803
-
-
Higgins, M.J.1
Baselga, J.2
-
38
-
-
59449084603
-
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
-
Borgquist S., Jögi A., Pontén F., Rydén L., Brennan D.J., Jirström K. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res 2008, 10:R79. 10.1186/bcr2146.
-
(2008)
Breast Cancer Res
, vol.10
, pp. R79
-
-
Borgquist, S.1
Jögi, A.2
Pontén, F.3
Rydén, L.4
Brennan, D.J.5
Jirström, K.6
-
39
-
-
84879411965
-
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
-
Bjarnadottir O., Romero Q., Bendahl P.O., Jirström K., Rydén L., Loman N., et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res. Treat 2013, 138:499-508. 10.1007/s10549-013-2473-6.
-
(2013)
Breast Cancer Res. Treat
, vol.138
, pp. 499-508
-
-
Bjarnadottir, O.1
Romero, Q.2
Bendahl, P.O.3
Jirström, K.4
Rydén, L.5
Loman, N.6
-
40
-
-
33747600872
-
Synergistic antimyeloma effects of zoledronate and simvastatin
-
Schmidmaier R., Simsek M., Baumann P., Emmerich B., Meinhardt G. Synergistic antimyeloma effects of zoledronate and simvastatin. Anticancer Drugs 2006, 17:621-629. 10.1097/01.cad.0000215058.85813.02.
-
(2006)
Anticancer Drugs
, vol.17
, pp. 621-629
-
-
Schmidmaier, R.1
Simsek, M.2
Baumann, P.3
Emmerich, B.4
Meinhardt, G.5
-
41
-
-
84863717286
-
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice
-
Ottewell P.D., Brown H.K., Jones M., Rogers T.L., Cross S.S., Brown N.J., et al. Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Res. Treat 2012, 133:523-536. 10.1007/s10549-011-1782-x.
-
(2012)
Breast Cancer Res. Treat
, vol.133
, pp. 523-536
-
-
Ottewell, P.D.1
Brown, H.K.2
Jones, M.3
Rogers, T.L.4
Cross, S.S.5
Brown, N.J.6
-
42
-
-
70350234896
-
Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone
-
Ottewell P.D., Woodward J.K., Lefley D.V., Evans C.A., Coleman R.E., Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol. Cancer Ther 2009, 8:2821-2832. 10.1158/1535-7163.MCT-09-0462.
-
(2009)
Mol. Cancer Ther
, vol.8
, pp. 2821-2832
-
-
Ottewell, P.D.1
Woodward, J.K.2
Lefley, D.V.3
Evans, C.A.4
Coleman, R.E.5
Holen, I.6
-
43
-
-
73549086519
-
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model
-
Ottewell P.D., Lefley D.V., Cross S.S., Evans C.A., Coleman R.E., Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int. J. Cancer 2010, 126:522-532. 10.1002/ijc.24756.
-
(2010)
Int. J. Cancer
, vol.126
, pp. 522-532
-
-
Ottewell, P.D.1
Lefley, D.V.2
Cross, S.S.3
Evans, C.A.4
Coleman, R.E.5
Holen, I.6
-
44
-
-
84977897354
-
Review series introduction
-
Polyak K. Review series introduction. Heterogeneity in breast cancer 2011, 121:2011-2013. 10.1172/JCI60534.3786.
-
(2011)
Heterogeneity in breast cancer
, vol.121
, pp. 2011-2013
-
-
Polyak, K.1
-
45
-
-
84860702956
-
The differential effects of statins on the metastatic behaviour of prostate cancer
-
Brown M., Hart C., Tawadros T., Ramani V., Sangar V., Lau M., et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br. J. Cancer 2012, 106:1689-1696. 10.1038/bjc.2012.138.
-
(2012)
Br. J. Cancer
, vol.106
, pp. 1689-1696
-
-
Brown, M.1
Hart, C.2
Tawadros, T.3
Ramani, V.4
Sangar, V.5
Lau, M.6
-
46
-
-
0038792653
-
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects
-
Denoyelle C., Hong L., Vannier J.-P., Soria J., Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br. J. Cancer 2003, 88:1631-1640. 10.1038/sj.bjc.6600925.
-
(2003)
Br. J. Cancer
, vol.88
, pp. 1631-1640
-
-
Denoyelle, C.1
Hong, L.2
Vannier, J.-P.3
Soria, J.4
Soria, C.5
-
47
-
-
0142245593
-
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels
-
van de Donk N.W.C.J., Kamphuis M.M.J., van Kessel B., Lokhorst H.M., Bloem A.C. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003, 102:3354-3362. 10.1182/blood-2003-03-0970.
-
(2003)
Blood
, vol.102
, pp. 3354-3362
-
-
van de Donk, N.W.C.J.1
Kamphuis, M.M.J.2
van Kessel, B.3
Lokhorst, H.M.4
Bloem, A.C.5
-
48
-
-
12344263772
-
Geranylgeranylated proteins are involved in the regulation of myeloma cell growth
-
Van De Donk N.W.C.J., Lokhorst H.M., Nijhuis E.H.J., Kamphuis M.M.J., Bloem A.C. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin. Cancer Res 2005, 11:429-439.
-
(2005)
Clin. Cancer Res
, vol.11
, pp. 429-439
-
-
Van De Donk, N.W.C.J.1
Lokhorst, H.M.2
Nijhuis, E.H.J.3
Kamphuis, M.M.J.4
Bloem, A.C.5
-
49
-
-
0344629822
-
Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells
-
Van De Donk N.W.C.J., Schotte D., Kamphuis M.M.J., Van Marion A.M.W., Van Kessel B., Bloem A.C., et al. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin. Cancer Res 2003, 9:5735-5748.
-
(2003)
Clin. Cancer Res
, vol.9
, pp. 5735-5748
-
-
Van De Donk, N.W.C.J.1
Schotte, D.2
Kamphuis, M.M.J.3
Van Marion, A.M.W.4
Van Kessel, B.5
Bloem, A.C.6
-
50
-
-
77956459044
-
Rac and Rho GTPases in cancer cell motility control
-
Parri M., Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun. Signal 2010, 8:23. 10.1186/1478-811X-8-23.
-
(2010)
Cell Commun. Signal
, vol.8
, pp. 23
-
-
Parri, M.1
Chiarugi, P.2
-
51
-
-
33646269011
-
Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases
-
Dunford J.E., Rogers M.J., Ebetino F.H., Phipps R.J., Coxon F.P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J. Bone Miner. Res 2006, 21:684-694. 10.1359/JBMR.060118.
-
(2006)
J. Bone Miner. Res
, vol.21
, pp. 684-694
-
-
Dunford, J.E.1
Rogers, M.J.2
Ebetino, F.H.3
Phipps, R.J.4
Coxon, F.P.5
-
52
-
-
26644442350
-
Mechanisms of statin-mediated inhibition of small G-protein function
-
Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem 2005, 280:34202-34209. 10.1074/jbc.M505268200.
-
(2005)
J. Biol. Chem
, vol.280
, pp. 34202-34209
-
-
Cordle, A.1
Koenigsknecht-Talboo, J.2
Wilkinson, B.3
Limpert, A.4
Landreth, G.5
-
53
-
-
84879711057
-
Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases
-
Zhu Y., Casey P.J., Kumar A.P., Pervaiz S. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis 2013, 4:e568. 10.1038/cddis.2013.103.
-
(2013)
Cell Death Dis
, vol.4
-
-
Zhu, Y.1
Casey, P.J.2
Kumar, A.P.3
Pervaiz, S.4
-
54
-
-
80055008724
-
PTEN regulates colorectal epithelial apoptosis through Cdc42 signalling
-
Deevi R., Fatehullah A., Jagan I., Nagaraju M., Bingham V., Campbell F.C. PTEN regulates colorectal epithelial apoptosis through Cdc42 signalling. Br. J. Cancer 2011, 105:1313-1321. 10.1038/bjc.2011.384.
-
(2011)
Br. J. Cancer
, vol.105
, pp. 1313-1321
-
-
Deevi, R.1
Fatehullah, A.2
Jagan, I.3
Nagaraju, M.4
Bingham, V.5
Campbell, F.C.6
-
55
-
-
0030798405
-
The small GTPase Cdc42 initiates an apoptotic signaling pathway in Jurkat T lymphocytes
-
Chuang T.H., Hahn K.M., Lee J.D., Danley D.E., Bokoch G.M. The small GTPase Cdc42 initiates an apoptotic signaling pathway in Jurkat T lymphocytes. Mol. Biol. Cell 1997, 8:1687-1698.
-
(1997)
Mol. Biol. Cell
, vol.8
, pp. 1687-1698
-
-
Chuang, T.H.1
Hahn, K.M.2
Lee, J.D.3
Danley, D.E.4
Bokoch, G.M.5
-
56
-
-
84902612645
-
Activation of RhoA,B,C by Yersinia Cytotoxic Necrotizing Factor (CNFy) induces apoptosis in LNCaP prostate cancer cells
-
Augspach A., List J.H., Wolf P., Bielek H., Schwan C., Elsässer-Beile U., et al. Activation of RhoA,B,C by Yersinia Cytotoxic Necrotizing Factor (CNFy) induces apoptosis in LNCaP prostate cancer cells. Toxins (Basel) 2013, 5:2241-2257. 10.3390/toxins5112241.
-
(2013)
Toxins (Basel)
, vol.5
, pp. 2241-2257
-
-
Augspach, A.1
List, J.H.2
Wolf, P.3
Bielek, H.4
Schwan, C.5
Elsässer-Beile, U.6
-
57
-
-
83555168297
-
Rac signaling in breast cancer: a tale of GEFs and GAPs
-
Wertheimer E., Gutierrez-Uzquiza A., Rosemblit C., Lopez-Haber C., Sosa M.S., Kazanietz M.G. Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell. Signal 2012, 24:353-362. 10.1016/j.cellsig.2011.08.011.
-
(2012)
Cell. Signal
, vol.24
, pp. 353-362
-
-
Wertheimer, E.1
Gutierrez-Uzquiza, A.2
Rosemblit, C.3
Lopez-Haber, C.4
Sosa, M.S.5
Kazanietz, M.G.6
-
58
-
-
84868019264
-
Targeting of Rac GTPases blocks the spread of intact human breast cancer
-
doi:520 [pii]
-
Katz E., Sims A.H., Sproul D., Caldwell H., Dixon M.J., Meehan R.R., et al. Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget 2012, 3:608-619. doi:520 [pii].
-
(2012)
Oncotarget
, vol.3
, pp. 608-619
-
-
Katz, E.1
Sims, A.H.2
Sproul, D.3
Caldwell, H.4
Dixon, M.J.5
Meehan, R.R.6
-
59
-
-
18644373689
-
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
-
Chen T., Berenson J., Vescio R., Swift R., Gilchick A., Goodin S., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol 2002, 42:1228. 10.1177/0091270002238765.
-
(2002)
J. Clin. Pharmacol
, vol.42
, pp. 1228
-
-
Chen, T.1
Berenson, J.2
Vescio, R.3
Swift, R.4
Gilchick, A.5
Goodin, S.6
-
60
-
-
83455163746
-
Pharmacological actions of statins: a critical appraisal in the management of cancer
-
Gazzerro P., Proto M.C., Gangemi G., Malfitano A.M., Ciaglia E., Pisanti S., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev 2012, 64:102-146. 10.1124/pr.111.004994.
-
(2012)
Pharmacol. Rev
, vol.64
, pp. 102-146
-
-
Gazzerro, P.1
Proto, M.C.2
Gangemi, G.3
Malfitano, A.M.4
Ciaglia, E.5
Pisanti, S.6
|